TITLE PAGE

Type of article: Research article

Full-length title:

Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in

southern France

Short title (for the running head): Emergence of a SARS-CoV-2 Delta/Omicon

recombinant

Author list: Philippe COLSON[1,2,3] ***, Pierre-Edouard FOURNIER**[1,2,4]**, Jeremy**

DELERCE[1]**, Matthieu MILLION**[1,2,3]**, Marielle BEDOTTO**[1]**, Linda HOUHAMDI**[1]**,**

Nouara YAHI[5]**, Jeremy BAYETTE**[6]**, Anthony LEVASSEUR**[1,2]**, Jacques FANTINI**[5]**,**

Didier RAOULT[1,2]**, Bernard LA SCOLA**[1,2,3] *****

Affiliations: [1] IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille,

France; [2] Aix-Marseille Univ., Institut de Recherche pour le Développement (IRD), Microbes

Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005 Marseille,

France; [3] Assistance Publique-Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13005

Marseille, France; [4] Aix-Marseille Université, INSERM UMR S 1072, 51 boulevard Pierre

Dramard, 13015 Marseille, France; [5] Aix-Marseille Univ., Institut de Recherche pour le

Développement (IRD), Vecteurs – Infections Tropicales et Méditerranéennes (VITROME),

27 boulevard Jean Moulin, 13005 Marseille, France; [6] LBM Inovie Labosud, 90 rue Nicolas

Chedville, 34070, Montpellier, France.

* Corresponding author: Bernard La Scola, IHU Méditerranée Infection, 19-21 boulevard

Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402; email:

bernard.la-scola@univ-amu.fr; Philippe Colson, IHU Méditerranée Infection, 19-21

boulevard Jean Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732

402; email: philippe.colson@univ-amu.fr

Key words: SARS-CoV-2; recombinant; variant; lineage; Delta; Omicron; Deltamicron;

epidemic

Word counts: abstract, 196; text, 2,560

Figures: 4; **Table:** 1; **References:** 43

ABSTRACT

Multiple SARS-CoV-2 variants have successively, or concommitantly spread worldwide since summer 2020. A few co-infections with different variants were reported and genetic recombinations, common among coronaviruses, were reported or suspected based on co-detection of signature mutations of different variants in a given genome. Here were report three infections in southern France with a Delta 21J/AY.4-Omicron 21K/BA.1 "Deltamicron" recombinant. The hybrid genome harbors signature mutations of the two lineages, supported by a mean sequencing depth of 1,163-1,421 reads and mean nucleotide diversity of 0.1-0.6%. It is composed of the near full-length spike gene (from codons 156-179) of an Omicron 21K/BA.1 variant in a Delta 21J/AY.4 lineage backbone. It is similar to those reported for 15 other patients sampled since January 2022 in Europe. Importantly, we cultured an isolate of this recombinant and sequenced its genome. It was observed by scanning electron microscopy. As it is misidentified with current variant screening qPCR, we designed and implemented for routine diagnosis a specific duplex qPCR. Finally, structural analysis of the recombinant spike suggested its hybrid content could optimize viral binding to the host cell membrane. These findings prompt further studies of the virological, epidemiological, and clinical features of this recombinant.

 TEXT

Introduction

The current SARS-CoV-2 pandemic has highlighted since the summer of 2020 the

successive or concomittant emergence of numerous viral variants, each causing a specific

epidemic (Lemey et al., 2021, Hodcroft et al., 2021; Colson et al., 2022b). Some of these

variants spread to become pandemic while others remained epidemic in a restricted

geographical area. The variants characterized so far have been shaped by nucleotide

substitutions, insertions or deletions. However, another major evolutionary mechanism of

RNA viruses is genetic recombination, which is very common among coronaviruses (Lai,

1996; Zhang et al., 2015; Xiao et al., 2017; So et al., 2019; Gribble et al., 2021). It requires

co-infection of the same host cell by two viruses, which may be two distinct mutants or

variants (Bentley et al., 2018). Therefore, the frequency of creation of recombinants between

two variants depends on the duration of their co-circulation, on the time until viral clearance,

and on the number of people exposed to both viruses. Co-infections with two variants were

reported including recently with SARS-CoV-2 Delta and Omicron variants (Jackson et al.,

2021; Francisco et al., 2021; Taghizadeh et al., 2021; Rockett et al., 2022). Furthermore,

genetic recombinations were reported or suspected, based on the concurrent detection in

consensus genomes of signature mutations of different mutants or variants (Yi, 2020; Yeh and

Contreras, 2020; VanInsberghe et al., 2020; Gallaher, 2020; Jackson et al., 2021; Haddad et

al., 2021; Makarenkov et al., 2021; Varabyou et al., 2021; Leary et al., 2021; Taghizadeh et

al., 2021; Lohrasbi-Nejad, 2022; Kreier, 2022; Ignatieva et al., 2022). A study detected up to

1,175 (0.2%) putative recombinant genomes among 537,360 genomes from the GISAID

database and estimated that up to 5% SARS-CoV-2 having circulated in the USA and UK

could be recombinants (VanInsberghe et al., 2020).

Two pandemic variants, Delta and Omicron 21K [Nextclade classification

(Aksamentov et al., 2021)]/BA.1 [Pangolin classification (Rambaut et al., 2020)], recently

succeeded each other as the predominant viruses but co-circulated for a period of several

weeks, creating conditions for co-infections and subsequently recombinations. This period

spanned between December 27th, 2021 and February 14th, 2022 in our geographical area, as

assessed by our SARS-CoV-2 genotypic surveillance based on variant-specific qPCR and

next-generation genomic sequencing (Colson et al., 2022b; Colson et al., 2022a). In January

2022, genomes harboring mutations from both Delta and Omicron 21K/BA.1 variants were

reported in Cyprus but it was questioned whether sequences might have resulted from

contamination (Kreier, 2022). Still, genomes being hybrids of these two variants and highly

similar between each other were reported since February 2022, and their number in the

GISAID database amounted to 15 as of 27/02/2022 (https://github.com/cov-lineages/pango-

designation/issues/444). We herein report three infections by a recombinant SARS-CoV-2

Delta 21K/AY.4-Omicron 21K/BA.1 whose genome is highly similar to the 15 previously

reported genomes and the isolation of the recombinant virus from one of the patients.

Materials and methods

Nasopharyngeal samples were collected from two patients in our university hospital

institute (Méditerranée Infection; https://www.mediterranee-infection.com/) and tested for

SARS-CoV-2 infection by real-time reverse transcription-PCR (qPCR) as previously

described (Colson et al., 2022b; Houhamdi et al., 2022). The third patient was sampled in a

private medical biology laboratory in southern France (Inovie Labosud, Montpellier, France).

qPCR assays that screen for SARS-CoV-2 variants were performed as recommended by

French public health authorities (https://www.data.gouv.fr/fr/datasets/donnees-de-

laboratoires-pour-le-depistage-indicateurs-sur-les-mutations/). In our center this included the

detection of spike mutation among which K417N (Thermo Fisher Scientific, Waltham, USA),

combined with testing with the TaqPath COVID-19 kit (Thermo Fisher Scientific) that target

viral genes ORF1, N (nucleocapsid) and S (spike), as previously reported (Colson et al.,

2022b; Colson et al., 2022a). The private medical laboratory used the ID SARS-CoV-2/VOC

Revolution Pentaplex assay (ID Solutions, Grabels, France) that detects spike mutations

K417N, L452R, and E484K (Pentaplex assay, ID Solution, France).

SARS-CoV-2 genomes were sequenced in the framework of genomic surveillance

implemented since February 2020 (Colson et al., 2022b) in our institute and as recommended

by French public health authorities since 2021

(https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-

emergen#block-356295). Next-generation sequencing was performed with the Illumina

COVID-seq protocol on the NovaSeq 6000 instrument (Illumina Inc., San Diego, CA, USA)

or with the Oxford Nanopore technology (ONT) on a GridION instrument (Oxford Nanopore

Technologies Ltd., Oxford, UK) combined with prior multiplex PCR amplification according

to the ARTIC procedure (https://artic.network/), as previously described (Colson et al.,

2022b; Colson et al., 2022a), with the ARTIC nCoV-2019 Amplicon Panel v4.1 of primers

(IDT, Coralville, IA, USA). Then, sequence read processing and genome analysis were

performed as previously described (Colson et al., 2022b; Colson et al., 2022a). Briefly, for

Illumina NovaSeq reads, base calling was performed with the Dragen Bcl Convert pipeline

[v3.9.3; https://emea.support.illumina.com/sequencing/sequencing_software/bcl-convert.html

(Illumina Inc.)], mapping was performed with the bwa-mem2 tool (https://github.com/bwa-

mem2/bwa-mem2) on the Wuhan-Hu-1 isolate genome (GenBank accession no.

NC_045512.2) then cleaned with Samtools (https://www.htslib.org/), variant calling was

carried out with freebayes (https://github.com/freebayes/freebayes) and consensus genomes

were built using Bcftools (https://samtools.github.io/bcftools/bcftools.html). ONT reads were

processed with the ARTIC field bioinformatics pipeline (https://github.com/artic-

network/fieldbioinformatics). Nucleotide and amino acid changes relatively to the Wuhan-

Hu-1 isolate genome were obtained using the Nextclade tool (https://clades.nextstrain.org/)

(Aksamentov et al., 2021; Rambaut et al., 2020). Nextstrain clades and Pangolin lineages

were determined using the Nextclade web application (https://clades.nextstrain.org/)

(Aksamentov et al., 2021) and the Pangolin tool (https://cov-lineages.org/pangolin.html)

(Rambaut et al., 2020), respectively. Genome sequences described here were deposited in the

GISAID sequence database (https://www.gisaid.org/) (EPI_ISL_10528736,

EPI_ISL_10531214, EPI_ISL_10529499, EPI_ISL_10640045) (Alm et al., 2020). The

Simplot software (https://sray.med.som.jhmi.edu/SCRoftware/SimPlot/) was used for

recombination analysis. Phylogeny was reconstructed by the nextstrain/ncov tool

(https://github.com/nextstrain/ncov) and visualized with Auspice

(https://docs.nextstrain.org/projects/auspice/en/stable/). Genomes the closest genetically to

those obtained here were selected among Delta 21J/AY.4 genomes recovered from GISAID

based on their mutation pattern, then incorporated in the phylogeny together with the genome

of the Wuhan-Hu-1 isolate.

SARS-CoV-2 culture isolation was performed by inoculating 200 µL of respiratory

sample on Vero E6 cells as previously described (La Scola et al., 2020). Cytopathic effect was

observed by inverted microscopy. Viral particles were visualized in the culture supernatant by

scanning electron microscopy with a SU5000 microscope (Hitachi High-Technologies

Corporation, Tokyo, Japan), as previously described (Colson et al., 2020).

Structural predictions of the spike protein were performed as previously described

(Fantini et al., 2021; Fantini et al., 2022; Colson et al., 2022a). Briefly, amino acid changes

were introduced in the framework of a complete 14-1,200 structure of the original SARS-

CoV-2 20B spike and missing amino acids were incorporated with the Robetta protein

structure prediction tool (https://robetta.bakerlab.org/) before energy minimization through

the Polak-Ribière algorithm.

A in house duplex qPCR assay specific of the SARS-CoV-2 recombinant was

designed that targets the genomes of the Delta 21J [targeted mutation: A11201G in the Nsp6

gene (corresponding to amino acid substitution T77A)] and the Omicron 21K/BA.1 [targeted

mutations: A23040G, G23048A, A23055G in the spike gene (Q493R, G496S, Q498R)]

variants. The sequences of the primers and probes (in 5'-3' orientation) are as follows: (i) for

the Delta 21J-targeting system: forward primer, CTGCTTTTGCAATGATGTTTGT; reverse

primer, TACGCATCACCCAACTAGCA; probe, 6FAM-

CTTGCCGCTGTAGCTTATTTTAAT (primers and probe concentrations in the mix were

200 nM and 150 nM, respectively); (ii) for the Omicron 21K/BA.1-targeting system: forward

primer, CCTTGTAATGGTGTTGAAGGTTTT; reverse primer,

CTGGTGCATGTAGAAGTTCAAAAG; probe, 6VIC-

TTTACGATCATATAGTTTCCGACCC (primers and probe concentrations in the mix were

250 nM and 200 nM, respectively).

This study was approved by the ethics committee of University Hospital Institute

Méditerranée Infection (No. 2022-001).

Results

The three case-patients were SARS-CoV-2-diagnosed on nasopharyngeal samples

collected in February 2022. Cycle threshold values (Ct) of diagnostic qPCR were between 20-

31. The patients were below 40 years of age. They resided in southern France and did not

travel abroad recently. They presented mild respiratory symptoms. Two were vaccinated

against SARS-CoV-2 (with two or three doses administered). Variant screening qPCR for the

2 samples collected in our institute showed positivity for the K417N mutation while the

TaqPath COVID-19 kit (Thermo Fisher Scientific, Waltham, USA) provided positive signals

for all three genes targeted (ORF1, S, and N). The third sample showed positivity for the

K417N mutation and negativity for the L452R and E484K mutations. Thus, overall, qPCR

carried out on the three samples were indicative of a Omicron variant.

Viral genomes (GISAID accession no. EPI_ISL_10528736, EPI_ISL_10531214, and

EPI_ISL_10529499) from two of the three patients were identical and clustered in the

phylogenetic analysis (**Figure 1**) despite no epidemiological link was documented between

these two patients. The third genome exhibited 5 nucleotide differences. These 3 genomes

were hybrids of Delta 21J AY.4 and Omicron 21K/BA.1 variant genomes (**Figure 2; Table

1**). At positions harboring mutations compared to the genome of the Wuhan-Hu-1 isolate,

mean sequencing depth was between 1,163-1,421 reads and mean prevalence of the

majoritary nucleotide was between 99.4-99.9% (with minimum values between 80.3-98.7%),

ruling out the concurrent presence of two variants in the samples either due to co-infection or

to contamination. In addition, the 3 genomes were phylogenetically-related to 15 Delta

21J/AY.4-Omicron 21K/BA.1 recombinant genomes previously detected in northern France,

Denmark, and the Netherlands, and obtained from samples collected between January 3rd,

2021 (in the French region Hauts-de-France) and February 16th, 2022 in Denmark (**Figure 1**).

Phylogenetic analysis and time estimation based on estimated SARS-CoV-2 mutation rate [≈1

mutation every 2 weeks (Van Dorp et al., 2020)] allowed estimating that the ancestor of this

recombinant might have emerged in December 2021.

In this SARS-CoV-2 recombinant, most of the spike gene was replaced in a Delta

21J/AY.4 matrix by an Omicron 21K/BA.1 sequence (**Figure 2**). Indeed, the recombination

sites were located between nucleotide positions 22,029-22,034 and 22,097 for the first one,

and between nucleotide positions 25,469 and 25,584 for the second one. These regions

corresponds to amino acids 156 to 179 of the spike protein and to amino acids 26 to 64 of the

ORF3 protein whose gene is contiguous to the spike gene. The Simplot recombination

analysis tool provided congruent results.

The respiratory sample from which the first recombinant genome was obtained was

inoculated on Vero E6 cells the day following recombinant identification, and cytopathic

effect was observed after 4 days (**Figures 3a, b**). The same day, supernatant was collected

and next-generation genome sequencing was performed using Nanopore technology on a

GridION instrument after PCR amplification with Artic primers, which allowed obtaining the

genome sequence of the viral isolate 8 h later (GISAID accession no. EPI_ISL_10640045). At

mutated positions compared to the Wuhan-Hu-1 isolate genome, mean sequencing depth was

2,771 reads and mean prevalence of the majoritary nucleotide was 99.1% (minimum, 95.1%),

and the consensus genome was identical to that obtained from the respiratory sample,

showing unambiguously that the virus isolated was the Delta 21J/AY.4-Omicron 21K/BA.1

recombinant. Finally, viral particles were observed in the culture supernatant by scanning

electron microscopy with a SU5000 microscope within minutes after supernatant collection

(**Figure 3c**).

The overall structure of the recombinant spike protein was predicted (**Figures 4a-c**).

When superimposed with the spike of the Omicron 21K/BA.1 variant, the main structural

changes were located in the N-terminal domain (NTD). In this region, the surface of the

recombinant spike protein is enlarged, flattened, and more electropositive, a property that is

characteristic of the Delta 21J/AY.4 NTD (**Figure 4c**). In the initial interaction of the virus

with the plasma membrane of the host cells, the NTD is attracted by lipid rafts, which

provides an electronegative landing platforms for the spike (Fantini et al., 2021; Fantini et al.,

2022). Thus, an increase in the electrostatic surface of the NTD is expected to accelerate the

binding of the virus to lipid rafts, which may confer a selective kinetic advantage against virus

competitors (Fantini et al., 2021). The receptor binding domain (RBD) of the recombinant is

clearly inherited from the Omicron 21K/BA.1 variant (**Figure 4c**). The consequence is also an

increase in the electrostatic surface potential of the RBD, which may facilitate the interaction

with the electronegative interface of the ACE-2 cellular receptor. Overall, this structural

analysis suggests that the recombinant virus could have been selected on the basis of kinetic

properties conferred by a convergent increase of the electrostatic potential of both the NTD

and the RBD, together with an enlargement of the NTD surface, all features that suggest an

optimization of virus binding to the host cell membrane.

Currently used qPCR screening assays were not able to discriminate this Delta

21J/AY.4-Omicron 21K/BA.1 recombinant and the Omicron 21K/BA.1 variant because the

Delta variant signature mutation detected is absent from the recombinant genome. Therefore,

we attempted to promptly implement a specific qPCR assay that could be used to detect the

recombinant for routine diagnosis use. This was achieved in one day by selecting qPCR

systems from our toolbox of dozens of in house qPCR systems that were designed since the

emergence of the first variant during summer 2020 to specifically target SARS-CoV-2

variants or mutants (Bedotto et al., 2021; Colson et al., 2022b). Two systems that target either

the Delta 21J variant or the Omicron BA.1 variant were combined in a duplex qPCR that can

screen for the recombinant. In preliminary assessment, both tested recombinant-positive

samples were positive for the Delta 21J and Omicron BA.1 targets. In addition, 7 Delta non-

21J-positive samples were negative for both targets, 4 Delta 21J-positive samples were

positive for the Delta 21J target but negative for the Omicron BA.1 target, and 3 Omicron

BA.1-positive samples were negative for the Delta 21J target but positive for the Omicron

BA.1 target.

Discussion

It is increasingly demonstrated that the genomes of most biological entities, whatever

their level of complexity, are mosaics of sequences from various origins (Raoult, 2011;

Merhej and Raoult, 2012; Feschotte et al., 2012; Roux et al., 2013; Jacobs et al., 2019). The

present observations show us in real life the recombination potential of SARS-CoV-2, already

largely established for other coronaviruses (Liu et al., 2013; Xiao et al., 2017; Lai, 1996;

Zhang et al., 2015; Gribble et al., 2021) and reported or suspected for SARS-CoV-2 (Yi,

2020; Yeh and Contreras, 2020; VanInsberghe et al., 2020; Gallaher, 2020; Jackson et al.,

2021; Haddad et al., 2021; Varabyou et al., 2021; Leary et al., 2021; Taghizadeh et al., 2021;

Lohrasbi-Nejad, 2022; Kreier, 2022; Ignatieva et al., 2022). SARS-CoV-2 recombinations

were difficult to spot when only genetically very similar viruses were circulating, as was the

case in Europe during the first epidemic episode with mutants derived from the Wuhan-Hu-1

virus. The increasing genetic diversity of SARS-CoV-2, the tremendous number of infections

at global and national levels, and the unprecedented global effort of genomic sequencing

(https://covariants.org/per-country) (Aksamentov et al., 2022; Hodcroft et al., 2021; Alm et

al., 2020; Colson et al., 2022b), raised the probability of detecting recombinants. Such

observations will probably make it possible in the short or medium term to assess the

recombination rate of SARS-CoV-2, whether there are recombination hotspots, and to what

extent recombinations between different variants can generate new viable, and epidemic

variants. This questions on the impact of recombinations on viral replication and

transmissibility, and on clinical severity, as well as on the virus ability to escape neutralizing

antibodies elicited by vaccines or a previous infection. In this view, culture isolation of

SARS-CoV-2 recombinants as was carried out here for the first time to our knowledge is of

primary importance. This will allow studying their phenotypic properties, among which their

replicative capacity in various cell lines, their sensitivity to antibodies, or their genetic

evolution *in vitro*. Concurrently, a high level of genomic surveillance must be maintained in

order to detect and characterize all recombination events and circulating recombinants, which

is a critical scientific and public health issue.

Acknowledgments

285   We are very grateful to Clio Grimaldier, Rita Zgheib, Claudia Andrieu, Ludivine Bréchard,

286   and Raphael Tola for their technical help.

Author contributions

Study conception and design: Philippe Colson, Pierre-Edouard Fournier, Jacques Fantini,

Didier Raoult, Bernard La Scola. Materials, data and analysis tools: Philippe Colson, Pierre-

Edouard Fournier, Jeremy Delerce, Matthieu Million, Marielle Bedotto, Linda Houhamdi,

Nouara Yahi, Jeremy Bayette, Jacques Fantini. Data analyses: Philippe Colson, Pierre-

Edouard Fournier, Jeremy Delerce, Marielle Bedotto, Anthony Levasseur, Jacques Fantini,

Didier Raoult, Bernard La Scola. Writing of the first draft of the manuscript: Philippe Colson,

Jacques Fantini, and Pierre-Edouard Fournier. All authors read, commented on, and approved

the final manuscript.

Funding

This work was supported by the French Government under the "Investments for the Future"

program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-

IAHU-03; by Région Provence Alpes Côte d'Azur and European funding FEDER PRIMMI

(Fonds Européen de Développement Régional-Plateformes de Recherche et d'Innovation

Mutualisées Méditerranée Infection), FEDER PA 0000320 PRIMMI; by Hitachi High-

Technologies Corporation, Tokyo, Japan; and by the French consortium on surveillance and

research on infections with emerging pathogens via microbial genomics (consortium relatif à

la surveillance et à la recherche sur les infections à pathogènes EMERgents via la

GENomique microbienne EMERGEN;

https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-emergen).

Data availability

The dataset generated and analyzed during the current study is available in the GISAID

database (https://www.gisaid.org/).

Conflicts of interest

Didier Raoult has a conflict of interest as having been a consultant for Hitachi High-

Technologies Corporation, Tokyo, Japan from 2018 to 2020. He is a scientific board member

of Eurofins company and a founder of a microbial culture company (Culture Top). All other

authors have no conflicts of interest to declare. Funding sources had no role in the design and

conduct of the study; collection, management, analysis, and interpretation of the data; and

preparation, review, or approval of the manuscript.

Ethics

This study has been approved by the ethics committee of the University Hospital Institute

Méditerranée Infection (No. 2022-001). Access to the patients' biological and registry data

issued from the hospital information system was approved by the data protection committee

of Assistance Publique-Hôpitaux de Marseille (APHM) and was recorded in the European

General Data Protection Regulation registry under number RGPD/APHM 2019-73.

REFERENCES

Aksamentov I, Roemer C, Hodcroft EB, Neher RA. Nextclade: clade assignment, mutation
calling and quality control for viral genomes. Zenodo 2021. doi:
https://doi.org/10.5281/zenodo.5607694.

Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, Melidou A,
Neher RA, O'Toole Á, Pereyaslov D; WHO European Region sequencing laboratories and
GISAID EpiCoV group; WHO European Region sequencing laboratories and GISAID
EpiCoV group. Geographical and temporal distribution of SARS-CoV-2 clades in the
WHO European Region, January to June 2020. Euro Surveill. 2020 Aug;25(32):2001410.

Bedotto M, Fournier PE, Houhamdi L, Colson P, Raoult D. Implementation of an in-house
real-time reverse transcription-PCR assay to detect the emerging SARS-CoV-2 N501Y
variants. J Clin Virol. 2021;140:104868.

Bentley K, Evans DJ. Mechanisms and consequences of positive-strand RNA virus
recombination. J Gen Virol. 2018;99:1345-1356.

Colson P, Delerce J, Beye M, Levasseur A, Boschi C, Houhamdi L, Tissot-Dupont H, Yahi
N, Million M, La Scola B, Fantini J, Raoult D, Fournier PE. First cases of infection with
the 21L/BA.2 Omicron variant in Marseille, France. medRxiv 2022a;
2022.02.08.22270495; doi: https://doi.org/10.1101/2022.02.08.22270495.

Colson P, Fournier PE, Chaudet H, Delerce J, Giraud-Gatineau A, Houhamdi L, Andrieu C,
Brechard L, Bedotto M, Prudent E, Gazin C, Beye M, Burel E, Dudouet P, Tissot-Dupont
H, Gautret P, Lagier JC, Million M, Brouqui P, Parola P, Fenollar F, Drancourt M, La
Scola B, Levasseur A, Raoult D. Analysis of SARS-CoV-2 variants from 24,181 patients
exemplifies the role of globalization and zoonosis in pandemics. Front Microbiol.
2022b;12:786233.

Colson P, Lagier JC, Baudoin JP, Bou Khalil J, La Scola B, Raoult D. Ultrarapid diagnosis,
microscope imaging, genome sequencing, and culture isolation of SARS-CoV-2. Eur J
Clin Microbiol Infect Dis. 2020 Aug;39(8):1601-1603.

Fantini J, Yahi N, Colson P, Chahinian H, La Scola B, Raoult D. The puzzling mutational
landscape of the SARS-2-variant Omicron. J Med Virol 2022 Jan 8. doi:
10.1002/jmv.27577. Epub ahead of print.

Fantini J, Yahi N, Azzaz F, Chahinian H. Structural dynamics of SARS-CoV-2 variants: A
health monitoring strategy for anticipating Covid-19 outbreaks. J Infect 2021;83:197-206.

Feschotte C, Gilbert C. Endogenous viruses: insights into viral evolution and impact on host
biology. Nat Rev Genet. 2012;13:283-96.

Francisco RDS Jr, Benites LF, Lamarca AP, de Almeida LGP, Hansen AW, Gularte JS,
Demoliner M, Gerber AL, de C Guimarães AP, Antunes AKE, Heldt FH, Mallmann L,
Hermann B, Ziulkoski AL, Goes V, Schallenberger K, Fillipi M, Pereira F, Weber MN, de
Almeida PR, Fleck JD, Vasconcelos ATR, Spilki FR. Pervasive transmission of E484K
and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two
different lineages in Rio Grande do Sul, Brazil. Virus Res. 2021;296:198345.

Gallaher WR. A palindromic RNA sequence as a common breakpoint contributor to copy-
choice recombination in SARS-COV-2. Arch Virol. 2020;165:2341-2348.

Gribble J, Stevens LJ, Agostini ML, Anderson-Daniels J, Chappell JD, Lu X, Pruijssers AJ,
Routh AL, Denison MR. The coronavirus proofreading exoribonuclease mediates
extensive viral recombination. PLoS Pathog. 2021;17(1):e1009226.

Haddad D, John SE, Mohammad A, Hammad MM, Hebbar P, Channanath A, Nizam R, Al-
Qabandi S, Al Madhoun A, Alshukry A, Ali H, Thanaraj TA, Al-Mulla F. SARS-CoV-2:
Possible recombination and emergence of potentially more virulent strains. PLoS One.
2021;16:e0251368.

Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,
Neher RA. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics.
2018;34:4121-4123.

Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, Reichmuth
ML, Bowen JE, Walls AC, Corti D, Bloom JD, Veesler D, Mateo D, Hernando A, Comas
I, González Candelas F; SeqCOVID-SPAIN consortium, Stadler T, Neher RA. Emergence
and spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature.
2021;595:707-712.

Houhamdi L, Gautret P, Hoang VT, Fournier PE, Colson P, Raoult D. Characteristics of the
first 1119 SARS-CoV-2 Omicron variant cases, in Marseille, France, November-December
2021. J Med Virol. 2022 Jan 20. doi: 10.1002/jmv.27613. Epub ahead of print.

Hodcroft E. 2012. CoVariants: SARS-CoV-2 mutations and variants of interest. Available
from: https://covariants.org/.

Ignatieva A, Hein J, Jenkins PA. Ongoing recombination in SARS-CoV-2 revealed through
genealogical reconstruction. Mol Biol Evol. 2022;39:msac028.

Jackson B, Boni MF, Bull MJ, Colleran A, Colquhoun RM, Darby AC, Haldenby S, Hill V,
Lucaci A, McCrone JT, Nicholls SM, O'Toole Á, Pacchiarini N, Poplawski R, Scher E,
Todd F, Webster HJ, Whitehead M, Wierzbicki C; COVID-19 Genomics UK (COG-UK)
Consortium, Loman NJ, Connor TR, Robertson DL, Pybus OG, Rambaut A. Generation
and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell.
2021;184:5179-5188.e8.

Jacobs GS, Hudjashov G, Saag L, Kusuma P, Darusallam CC, Lawson DJ, Mondal M, Pagani
L, Ricaut FX, Stoneking M, Metspalu M, Sudoyo H, Lansing JS, Cox MP. Multiple deeply
divergent Denisovan ancestries in Papuans. Cell. 2019;177:1010-1021.e32.

Kreier F. Deltacron: the story of the variant that wasn't. Nature. 2022;602:19.

La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult
D. Viral RNA load as determined by cell culture as a management tool for discharge of
SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis.
2020;39:1059-1061.

Lai MMC. Recombination in large RNA viruses: Coronaviruses. Semin Virol. 1996;7:381-
388.

Leary S, Gaudieri S, Parker MD, Chopra A, James I, Pakala S, Alves E, John M, Lindsey BB,
Keeley AJ, Rowland-Jones SL, Swanson MS, Ostrov DA, Bubenik JL, Das S, Sidney J,
Sette A; COVID-19 Genomics UK (COG-UK) consortium, de Silva TI, Phillips E, Mallal
S. Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R
variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2
at both protein and RNA level. Pathog Immun. 2021;6:27-49.

Lemey P, Ruktanonchai N, Hong SL, Colizza V, Poletto C, Van den Broeck F, Gill MS, Ji X,
Levasseur A, Oude Munnink BB, Koopmans M, Sadilek A, Lai S, Tatem AJ, Baele G,
Suchard MA, Dellicour S. Untangling introductions and persistence in COVID-19
resurgence in Europe. Nature. 2021;595:713-717.

Liu X, Shao Y, Ma H, Sun C, Zhang X, Li C, Han Z, Yan B, Kong X, Liu S. Comparative
analysis of four Massachusetts type infectious bronchitis coronavirus genomes reveals a
novel Massachusetts type strain and evidence of natural recombination in the genome.
Infect Genet Evol. 2013;14:29-38.

Lohrasbi-Nejad A. Detection of homologous recombination events in SARS-CoV-2.
Biotechnol Lett. 2022 Jan 17:1–16. doi: 10.1007/s10529-021-03218-7. Epub ahead of
print.

Makarenkov V, Mazoure B, Rabusseau G, Legendre P. Horizontal gene transfer and
recombination analysis of SARS-CoV-2 genes helps discover its close relatives and shed
light on its origin. BMC Ecol Evol. 2021;21:5.

Merhej V, Raoult D. Rhizome of life, catastrophes, sequence exchanges, gene creations, and
giant viruses: how microbial genomics challenges Darwin. Front Cell Infect Microbiol.
2012;2:113.

Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. A
dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic
epidemiology. Nat Microbiol. 2020;5:1403-1407.

Raoult D. A viral grandfather: genomics in 2010 contradict Darwin's vision of evolution. Eur
J Clin Microbiol Infect Dis. 2011;30:935-6.

Rockett, Jenny Draper, Mailie Gall, Eby M Sim, Alicia Arnott, Jessica E Agius, Jessica
Johnson-Mackinnon, Elena Martinez, Alexander P Drew, Clement Lee, Christine Ngo,
Marc Ramsperger, Andrew N Ginn, Qinning Wang, Michael Fennell, Danny Ko, Linda
Huston, Lukas Kairaitis, Edward C Holmes, Matthew N O'Sullivan, Sharon C-A Chen, Jen
Kok, Dominic E Dwyer, Vitali Sintchenko. Co-infection with SARS-CoV-2 Omicron and
Delta Variants revealed by genomic surveillance. medRxiv 2022; 2022.02.13.22270755;
doi: https://doi.org/10.1101/2022.02.13.22270755.

Roux S, Enault F, Bronner G, Vaulot D, Forterre P, Krupovic M. Chimeric viruses blur the
borders between the major groups of eukaryotic single-stranded DNA viruses. Nat
Commun. 2013;4:2700.

So RTY, Chu DKW, Miguel E, Perera RAPM, Oladipo JO, Fassi-Fihri O, Aylet G, Ko RLW,
Zhou Z, Cheng MS, Kuranga SA, Roger FL, Chevalier V, Webby RJ, Woo PCY, Poon
LLM, Peiris M. Diversity of dromedary camel coronavirus HKU23 in African camels
revealed multiple recombination events among closely related betacoronaviruses of the
subgenus Embecovirus. J Virol. 2019;93:e01236-19.

Taghizadeh P, Salehi S, Heshmati A, Houshmand SM, InanlooRahatloo K, Mahjoubi F,
Sanati MH, Yari H, Alavi A, Jamehdar SA, Dabiri S, Galehdari H, Haghshenas MR,
Hashemian AM, Heidarzadeh A, Jahanzad I, Kheyrani E, Piroozmand A, Mojtahedi A,
Nikoo HR, Rahimi Bidgoli MM, Rezvani N, Sepehrnejad M, Shakibzadeh A, Shariati G,
Seyyedi N, MohammadSaleh Zahraei S, Safari I, Elahi E. Study on SARS-CoV-2 strains in
Iran reveals potential contribution of co-infection with and recombination between
different strains to the emergence of new strains. Virology. 2021;562:63-73.

van Dorp L, Richard D, Tan CCS, Shaw LP, Acman M, Balloux F. No evidence for increased
transmissibility from recurrent mutations in SARS-CoV-2. Nat Commun. 2020;11:5986.

VanInsberghe D, Neish AS, Lowen AC, Koelle K. Recombinant SARS-CoV-2 genomes are
currently circulating at low levels. bioRxiv 2021;2020.08.05.238386. doi:
10.1101/2020.08.05.238386.

Varabyou A, Pockrandt C, Salzberg SL, Pertea M. Rapid detection of inter-clade
recombination in SARS-CoV-2 with Bolotie. Genetics. 2021;218:iyab074.

Xiao Y, Rouzine IM, Bianco S, Acevedo A, Goldstein EF, Farkov M, Brodsky L, Andino R.
RNA recombination enhances adaptability and is required for virus spread and virulence.
Cell Host Microbe. 2017;22:420.

Yeh TY, Contreras GP. Emerging viral mutants in Australia suggest RNA recombination
event in the SARS-CoV-2 genome. Med J Aust. 2020;213:44-44.e1.

Yi H. 2019 Novel coronavirus is undergoing active recombination. Clin Infect Dis.
2020;71:884-887.

Zhang Y, Li J, Xiao Y, Zhang J, Wang Y, Chen L, Paranhos-Baccalà G, Ren L, Wang J.
Genotype shift in human coronavirus OC43 and emergence of a novel genotype by natural
recombination. J Infect. 2015;70:641-50.

 FIGURE LEGEND

Figure 1. Phylogeny reconstruction based on SARS-CoV-2 Delta 21J/AY.4-Omicron

21K/BA.1 genomes.

Phylogenetic analysis was performed using the nextstrain/ncov tool

(https://github.com/nextstrain/ncov) then visualized with Auspice

(https://docs.nextstrain.org/projects/auspice/en/stable/). X-axis shows time. Sequences are

labelled with GISAID identifiers ((https://www.gisaid.org/) (Alm et al., 2020).

Figure 2. Schematic of the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1

recombinant genome.

a. Map of the SARS-CoV-2 genome.

b. Schematic representation of parental and recombinant genomes.

c. Mutations in the three Delta 21J/AY.4-Omicron 21K/BA1 recombinant genomes. Adapted

from screenshots of the nextclade web application output (https://clades.nextstrain.org)

(Hadfield et al., 2018; Aksamentov et al., 2021). Color codes for nucleotide mutations and are

marked regions as follows: Green: U; yellow: G; blue: C; red: A; grey: deletions or uncovered

regions.

Figure 3. Microscopy images of the virus cytopathic effect (a, b) and of a viral particle

(c) in culture of the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1 recombinant on

Vero E6 cells.

a. Absence of cytopathic effect (negative control: absence of virus); b. Cytopathic effect

observed 4 days post-inoculation on Vero E6 cells of the respiratory sample of the first patient

for whom the SARS-CoV-2 Delta 21J/AY.4-Omicron 21K/BA.1 recombinant was identified.

c. Scanning electron microscopy image was obtained with a SU5000 microscope (Hitachi

High-Technologies Corporation, Tokyo, Japan).

Figure 4. Schematic of the predicted structure of the spike protein of the SARS-CoV-2

Delta 21J/AY.4-Omicron 21K/BA.1 recombinant

a. Overall structure of the recombinant spike protein. The secondary structure is in grey,

mutated amino acids are in blue. NTD, N-terminal domain; RBD, receptor binding domain;

S1-S2, cleavage site.

b. Superimposition of the secondary structure of the Omicron 21K/BA.1 variant (in cyan) and

recombinant (in red) spike proteins. NTD, N-terminal domain; RBD, receptor binding

domain.

c. Comparison of the electrostatic surface potential of the spike proteins in Delta 21J/AY.4

lineage, Omicron 21K/BA.1 variant, and in the recombinant. The color scale (negative in red,

positive in blue, neutral in white) is indicated. NTD, N-terminal domain; RBD, receptor

binding domain.

TABLE

Table 1. Nucleotide and amino acid changes in the Deltamicron recombinant according to their presence/absence in the Delta 21J/AY.4 lineage and the Omicron 21K/BA.1 variant.

SARS-CoV-2 genes or genome regions	Nucleotide changes	Amino acid changes	Specific of the Delta 21J/AY.4 lineage ancestor before recombination	Present in the Delta 21J/AY.4 lineage	Present in the Omicron 21K/BA.1 variant
5'UTR	G210U	/		X	
5'UTR	C241U	/		X	X
ORF1a	A1321C	E352D	X		
ORF1a	C3037U	/		X	X
ORF1a	G4181U	A1306S		X	
ORF1a	C6402U	P2046L		X	
ORF1a	C7124U	P2287S		X	
ORF1a	C7851U	A2529V		X	
ORF1a	A8723G	I2820V	X		
ORF1a	C8986U	/		X	
ORF1a	G9053U	V2930L		X	
ORF1a	C10029U	T3255I		X	X
ORF1a	A11201G	T3646A		X	
ORF1a	A11332G	/		X	
ORF1b	C14407U	P314F		X	X
ORF1b	C14408U	P314F		X	X
ORF1b	U15264C	/	X		
ORF1b	G15451A	G662S		X	
ORF1b	C16466U	P1000L		X	
ORF1b	C19220U	A1918V		X	
S	C21618G	T19R		X	
S	G21641U	A27S	X		
S	C21846U	T95I		X	X
S	G21987A	G142D		X	
S	GAGUUCA22028G	EFR156G		X	
S	AAUU22193A	NL211I			X
S	U22204UGAGCCAGAA	INS214EPE			X
S	G22578A	G339D			X
S	UC22673CU	S371L			X
S	U22679C	S373P			X
S	C22686U	S375F			X
S	G22813U	K417N			X
S	U22882G	N440K			X
S	G22898A	G446S			X
S	G22992A	S477N			X
S	C22995A	T478K		X	X
S	A23013C	E484A			X
S	A23040G	Q493R			X
S	G23048A	G496S			X
S	A23055G	Q498R			X
S	A23063U	N501Y			X
S	U23075C	Y505H			X
S	C23202A	T547K			X
S	A23403G	D614G		X	X
S	C23525U	H655Y			X
S	U23599G	N679K			X
S	C23604A	P681H			X
S	C23854A	N764K			X
S	G23948U	D796Y			X
S	C24130A	N856K			X
S	A24424U	Q954H			X
S	U24469A	N969K			X
S	C24503U	L981F			X
S	C25000U	/			X
ORF3a	C25667U	S92L	X		
ORF3a	G25855U	D155Y	X		
M	U26767C	I82T		X	
ORF7a	U27638C	V82A		X	
ORF7a	C27752U	T120I		X	
ORF7b	C27874U	T40I		X	
ORF8	AGAUUUC28247A	DF119Del		X	
Intergenic region	UA28270U	/		X	
N	A28461G	D63G		X	
N	G28881U	R203M		X	
N	G28916U	G215C		X	
N	G29402U	D377Y		X	
Intergenic region	G29540A	/	X		
ORF10	G29645U	/	X		
3'UTR	G29742U	/		X	

/, no change; X, present; UTR, untranslated region; S gene region is indicated by a grey background

Fig. 1

Fig. 2

a. Map of the SARS-CoV-2 genome

b. Schematic of parental and recombinant genomes

Parental Delta 21J AY.4 genome

Delta 21J AY.4 - Omicron 21K/BA1 recombinant genomes

Parental Omicron 21K/BA.1 genome

c. Nucleotide mutations in the three Delta 21J AY.4 / Omicron 21K/BA1 recombinant genomes

relatively to Wuhan-Hu-1 isolate genome

EPI_ISL_10528736
EPI_ISL_10529499
EPI_ISL_10531214

relatively to Delta 21J AY.4 variant genome

EPI_ISL_10528736
EPI_ISL_10529499
EPI_ISL_10531214

relatively to Omicron 21K/BA.1 variant genome

EPI_ISL_10528736
EPI_ISL_10529499
EPI_ISL_10531214

Fig. 3

a.

b.

c.

SU5000 10.0kV 5.5mm x25.0k SE(L)   2.00μm

Fig. 4

a.

NTD

E156/F157⁻

T19R

RBD

N211⁻

S1-S2→

S477N

Recombinant spike

b.

NTD   RBD

Omicron: cyan
Recombinant: red

c.

Small surface

Larger surface

NTD   RBD

NTD   RBD

NTD   RBD

Electronegative area

Increased surface potential

+
−

Delta
21J AY.4

Omicron
BA.1

Recombinant
Delta/Omicron